Suppr超能文献

无谷氨酰胺酶天冬酰胺酶(MSMEG_3173)的特性分析

Characterization of Glutaminase-Free Asparaginase (MSMEG_3173).

作者信息

Rezende Corrêa Paloma, Schwarz Marcos Gustavo Araujo, Antunes Deborah, Piñero Sindy Licette, Castro Silva Marlon, Mangabeira Crescêncio Mayra, Guimarães Ana Carolina Ramos, Degrave Wim Maurits, Mendonça-Lima Leila

机构信息

Laboratório de Genômica Funcionale Bioinformática, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-900, Brazil.

出版信息

ACS Omega. 2024 Sep 12;9(38):40214-40225. doi: 10.1021/acsomega.4c06459. eCollection 2024 Sep 24.

Abstract

l-asparaginase is an enzyme catalyzing the hydrolysis of l-asparagine into l-aspartate and ammonia, which is of great therapeutic importance in tumor treatment. However, commercially available enzymes are associated with adverse effects, and searching for a new l-asparaginase with better pharmaceutical properties was the aim of this work. The coding sequence for l-asparaginase (MsA) was cloned and expressed. The recombinant protein showed high activity toward l-asparagine, whereas none was detected for l-glutamine. The enzymatic properties ( = 1.403 ± 0.24 mM and = 708.1 ± 25.05 s) indicate that the enzyme would be functional within the expected blood l-asparagine concentration, with good activity, as shown by . The pH and temperature profiles suggest its use as a biopharmaceutical in humans. Molecular dynamics analysis of the MsA model reveals the formation of a hydrogen bond network involving catalytic residues with l-asparagine. However, the same is not observed with l-glutamine, mainly due to steric hindrance. Additionally, the structural feature of residue 119 being a serine rather than a proline has significant implications. These findings help explain the low glutaminase activity observed in MsA, like what is described for the enzyme. This establishes mycobacterial asparaginases as key scaffolds to develop biopharmaceuticals against acute lymphocytic leukemia.

摘要

L-天冬酰胺酶是一种催化L-天冬酰胺水解为L-天冬氨酸和氨的酶,在肿瘤治疗中具有重要的治疗意义。然而,市售的酶存在不良反应,寻找具有更好药学性质的新型L-天冬酰胺酶是本研究的目的。克隆并表达了L-天冬酰胺酶(MsA)的编码序列。重组蛋白对L-天冬酰胺表现出高活性,而对L-谷氨酰胺未检测到活性。酶学性质(Km = 1.403 ± 0.24 mM,kcat = 708.1 ± 25.05 s)表明该酶在预期的血液L-天冬酰胺浓度范围内具有功能,活性良好,如所示。pH和温度曲线表明其可作为人类生物药物使用。MsA模型的分子动力学分析揭示了涉及催化残基与L-天冬酰胺的氢键网络的形成。然而,L-谷氨酰胺未观察到同样的情况,主要是由于空间位阻。此外,残基119为丝氨酸而非脯氨酸的结构特征具有重要意义。这些发现有助于解释MsA中观察到的低谷氨酰胺酶活性,就像对酶所描述的那样。这确立了分枝杆菌天冬酰胺酶作为开发抗急性淋巴细胞白血病生物药物的关键支架。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e102/11425952/b7a40d687e18/ao4c06459_0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验